OncoDxRx

OncoDxRx is a patient-centered, innovation-driven liquid biopsy company. We develop, validate and offer exclusive, transformative and build-for-purpose diagnostics and therapeutics to the huge, unmet genetic healthcare market. Our current pipeline covers early cancer detection, treatment selection, monitoring recurrence to therapeutics. PGA (patient-derived gene expression-informed anti-cancer drug efficacy) is the flagship assay which can provide comprehensive anti-cancer drug efficacy data within 5 days and improve the clinical-benefit rate for cancer patients. PGA’s unprecedented potential of selecting the optimal regimen among hundreds of anti-cancer drugs for individual patients based on their own gene expression signatures is truly a breakthrough. For cancer early detection, OncoDxRx scientists have identified 10 CpG methylation biomarkers with AUC of 0.895 for 14 cancer types. One-of-a-kind assays for MRD, DNA repair activity (HRR and/or MMR), tissue-of-origin as well as cancer drug discovery are also progressing as planned. OncoDxRx is seeking for investors/buyers/partners to further our mission.